Savient Pharmaceuticals Inc (SVNT) - Description of business

Company Description
Also, in January 2006 we completed the sale to Indevus Pharmaceuticals, Inc. (“Indevus”) of Delatestryl, our former injectable testosterone product for male hypogonadism. Under the terms of the sale, Indevus paid us an initial payment of $5 million and a portion of net sales of the product for the first three years following closing of the transaction based on an escalating scale.